CervoMed CRVO
NASDAQ CRVO
$2.97 +0.09 (+3.12%)
At close: Sep 30, 2026 · 4:00 PM EDT

CervoMed (CRVO) Receivables - Other (2012 - 2025)

Updated

CervoMed (CRVO) reported Receivables - Other of $426,993 for Q4 2025, down 81.1% from $2.25 million a year earlier and down 68.6% from the prior quarter.

Analysis

CervoMed (CRVO) Receivables - Other (2012 - 2025) Analysis & Trends

Dating back to Q3 2012, CervoMed's Receivables - Other record includes 13 quarters.

  • By year, Receivables - Other came in at $2.25 million in FY2024 (+146.3%) and $915,404 in FY2023.
  • The Q4 2025 figure ranks as the lowest quarterly Receivables - Other since Q3 2024.
  • Per Business Quant data, the three quarters before Q4 2025 came in at $1.36 million (Q3 2025), $2.36 million (Q2 2025) and $1.63 million (Q1 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn
10 CervoMed 30.43 Mn 30.43 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2025 426,993.00
Sep 30, 2025 1.36 Mn
Jun 30, 2025 2.36 Mn
Mar 31, 2025 1.63 Mn
Dec 31, 2024 2.25 Mn
Sep 30, 2024 264,148.00
Dec 31, 2023 915,404.00
Dec 31, 2013 2,020.00
Sep 30, 2013 53,013.00
Jun 30, 2013 58,693.00
Mar 31, 2013 71,946.00
Dec 31, 2012 71,946.00
Sep 30, 2012 538,515.00
API Access

CervoMed Receivables - Other API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=receivables-other&ticker=CRVO&period=max&api_key=YOUR_API_KEY